These Are The 11 Biggest Psychedelics News And Trends You May Have Missed Last Year
What a year for psychedelics!
Psyched: First Ayahuasca Pill Created, Psychedelics Legalization Predicted, UK’s Research Support And More
Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans
The first medical-grade drug candidate of the psychedelic ayahuasca is being developed.
Awakn Unveils Q3 Results, Touts Revenue Growth, R&D Progress, Commercial Plans
Psychedelics biotech Awakn Life Sciences Corp. (OTCQB: AWKNF) shared its financial results and business highlights for a three-month period that ended Oct. 31, 2022.
Financials showed:
UK Supports Psychedelic Research With Phase 3 Trial In Federal Health Sites
Awakn Life Sciences Corp.
Psyched: Fed Guidelines And Research Production Quotas, Protests In Canada, Cal’s Decrim Project
Psychedelic Research & Fed Funding By The National Institute Of Mental Health
The National Institute of Mental Health (NIMH) named the types of psychedelics studies to which it would grant funds and further guidance for pre-clinical research and studies with young participants.
Europe To Have Expanded Access To Psychedelic-Assisted Therapy With New Norway Clinic
Psychedelics biotech Awakn Life Sciences Corp.
Psyched: Full-Dose & Microdosing LSD Studies, Research Scope For Fed Funding, Consumption Sites And More
LSD Research Ramps Up: Full-Dose & Microdosing For Alzheimer's Studies Led By Beckley Foundation Coming Soon
A Leading Ketamine Treatment Clinic For Alcoholism Is Expanding: Here’s The Latest
A psychedelics R&D biotech company, known for providing novel treatments for addictions, is opening a new ketamine clinic.
Psyched: Colorado Legalizes Psychedelics, NYC Treats Alcoholism With Ketamine, $30M Series A For Startup
Colorado Voters Approve Initiative To Legalize And Regulate Psychedelics
Can Ketamine Treat Alcohol Addiction? In-Clinic Therapy Vs. Retreats
(Part four of a four-part series - Read part three)